The History of Ibogaine: From Bwiti Root Bark to Stanford

Ibogaine has been used in Bwiti ceremony for centuries. A French chemist isolated the alkaloid in 1901. An American heroin addict discovered its anti-addiction properties in 1962 by accident. The US government scheduled it in 1970 before any clinical evidence existed. In February 2023, Stanford published findings that no conventional psychiatric treatment has matched.

Understanding that arc is useful. It explains why the research base looks the way it does, what the current clinical trials represent, and why ibogaine is not scheduled in Canada the way it is in the United States.

The Bwiti tradition

Tabernanthe iboga is native to Gabon, Cameroon, and the Republic of Congo. The root bark has been a sacrament of Missoko Bwiti—the dominant spiritual tradition in Gabon, with approximately two million practitioners—for centuries, possibly much longer.

In Bwiti initiation, iboga root bark is consumed in larger quantities than in a Western ibogaine ceremony—enough to produce a visionary state lasting 24 to 36 hours. The purpose is not symptom reduction. It is initiation: an encounter with ancestors, with personal history, with what the person has been avoiding. The ceremony completes a process that, in the Bwiti framework, adults must undergo to become full members of their community.

The distinction between Bwiti-rooted iboga ceremony and clinical ibogaine treatment is real and matters. Whole root bark contains more than 30 alkaloids whose proportions and interactions produce a different experience from isolated ibogaine HCl. Both carry the same absolute cardiac contraindications. Neither is medically less serious than the other.

Isolation as a compound: 1901

In 1901, French chemists Dybowski and Landrin isolated the primary alkaloid from Tabernanthe iboga root bark and named it ibogaine. This was part of a broader programme of colonial pharmacology—European powers cataloguing plants used by colonised populations for compounds of potential commercial value.

The isolated alkaloid attracted brief interest as a low-dose stimulant. It was sold briefly in France under the trade name Lambarène. No significant medical application was identified. The compound stayed on the margins of pharmacology for sixty years after its isolation.

How the anti-addiction property was discovered

In 1962, Howard Lotsof was a 19-year-old heroin addict in New York. A chemist acquaintance provided him with ibogaine, which was not yet a controlled substance. Lotsof consumed it expecting a hallucinogenic experience.

Thirty-six hours later, his opioid withdrawal symptoms had stopped. His craving had stopped with them. Not reduced—stopped.

He arranged for six other heroin-dependent people he knew to try it. Five had the same experience: spontaneous opioid withdrawal resolution and substantially reduced craving, with no tapering protocol and no substitution pharmacology.

Lotsof spent the following decades attempting to establish ibogaine as an anti-addiction treatment. He filed patents on the therapeutic application in 1985. He collaborated with researchers in the Netherlands and the United States. He documented the same finding repeatedly: ibogaine produced rapid resolution of opioid withdrawal and sustained reductions in craving that outlasted any conventional pharmacological explanation. He did not succeed in getting ibogaine into standard clinical medicine during his lifetime. He died in 2010.

The 1970 scheduling decision

In 1970, the Nixon administration passed the Controlled Substances Act. Ibogaine was placed on Schedule I—alongside heroin and LSD—designating no accepted medical use, high abuse potential, and no safe use even under medical supervision.

The scheduling decision was made without clinical evidence. There was no randomised trial. There was no established safety profile from medical use. There was Lotsof's unpublished observations, and there was the political climate of the War on Drugs, which scheduled first and asked questions later.

The consequences were significant. Schedule I status effectively ended US clinical research for decades. Researchers needed special DEA exemptions that were difficult to obtain. Clinical trials could not be conducted in American facilities. The opportunity cost cannot be calculated precisely. It is not zero.

The fact that ibogaine research has been constrained by scheduling law for 50 years is a policy failure, not a scientific verdict. The evidence that exists—despite the obstacles—is remarkably consistent in direction. Citing the absence of a large-scale randomised trial as evidence ibogaine does not work confuses a regulatory obstruction with a scientific finding.

Research despite the obstacles

Clinical research continued outside the US. The Netherlands hosted trials in the 1990s. Providers in Mexico, Costa Rica, and Canada built operational experience over decades. Observational studies accumulated.

The consistent finding replicated Lotsof's: ibogaine produced rapid interruption of opioid withdrawal symptoms and sustained craving reduction that outlasted any pharmacokinetic explanation from the drug's elimination half-life. The mechanism—later identified as upregulation of glial cell line-derived neurotrophic factor (GDNF) and activity at multiple receptor systems including mu-opioid—explained the persistence.

Researchers published preliminary studies showing reduced opioid use following ibogaine treatment. The evidence was consistent across populations and settings. None of it was definitive. The direction never changed.

Ibogaine is not listed under Canada's Controlled Drugs and Substances Act. This is why ibogaine ceremony in Canada operates legally under current law, while US providers must use facilities in Mexico or elsewhere to administer it.

What the Stanford study found

In February 2023, Nature Medicine published findings from Stanford researchers that shifted the conversation. Thirty special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression received ibogaine treatment at a facility in Mexico—US researchers could not administer it domestically. At one month post-treatment: PTSD symptoms decreased an average of 88%. Depression decreased 87%. Anxiety decreased 81%.

For context: conventional antidepressant research considers a 50% reduction in depression scores a strong response. The Stanford numbers are nearly double that threshold, in a population where conventional treatment had not worked.

Special operations veterans are not a population that enters things naively. They have been through treatment programmes. They have been given diagnoses and medications. Many arrive sceptical that anything is going to work—not because they lack motivation, but because they have accumulated evidence that the available options are inadequate. That scepticism, earned through years of failed treatments, did not prevent the outcomes documented at one month.

The study has real limitations. Thirty people is not a definitive population. There is no placebo arm. The measurement point is one month—the six-month and one-year durability depends significantly on what is done during the integration period that follows ceremony. These limitations make the findings preliminary-but-compelling, not dismissible.

Texas subsequently committed $50 million USD to ibogaine clinical trials at UTMB, UTHealth Houston, Texas A&M, and Baylor University. This represents the largest public investment in ibogaine research in its 120-year documented Western history.

Who this history does not apply to

The history of ibogaine is not an argument that everyone with PTSD, depression, or opioid dependence should pursue ibogaine ceremony.

Absolute contraindications exist regardless of research trajectory or personal urgency. You are not an appropriate candidate if you have QT prolongation or significant cardiac arrhythmia on EKG, a recent myocardial infarction, severe liver or kidney disease, active psychosis or a schizophrenia-spectrum disorder, or pregnancy. You are not a candidate if you are currently on SSRIs or SNRIs without completing a supervised taper. You are not a candidate if you are on methadone without completing a specific transition protocol that requires weeks of physician supervision. Lithium is also an absolute contraindication.

The people most drawn to this history—who have read the Stanford data, who have tried every available treatment, who have arrived at ibogaine as a last option—are sometimes the people whose conditions make ceremony genuinely dangerous. That urgency is understood. It does not remove the contraindications. A cardiac EKG is required before any ceremony, and it is required precisely because the people who most want to proceed are not always the people for whom it is safe to do so.

If you are on methadone, on active SSRIs, or have an unresolved cardiac concern, the right next step is not a ceremony application. It is a conversation with a physician about what a safe pathway to ceremony actually looks like, and whether one exists.

Is this right for you?

If you are free of the above contraindications and have been exploring ibogaine seriously, the practical next step is an intake conversation.

Review what ceremony involves, read the FAQ, and understand what integration support looks like in the period following ceremony. If you are ready to begin a screening conversation, you can apply here. If the screening conversation ends in a no, that is the answer—stated directly and without softening it.